Share on StockTwits

Stock analysts at Robert W. Baird hoisted their price objective on shares of PAREXEL International (NASDAQ:PRXL) from $64.00 to $66.00 in a report issued on Thursday. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 21.48% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of PAREXEL International from $58.00 to $59.00 in a research note on Thursday. Separately, analysts at KeyCorp initiated coverage on shares of PAREXEL International in a research note on Wednesday, July 2nd. They set a “hold” rating on the stock. Finally, analysts at Wells Fargo & Co. upgraded shares of PAREXEL International to a “priority list” rating in a research note on Thursday, June 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $56.02.

PAREXEL International (NASDAQ:PRXL) traded up 0.26% on Thursday, hitting $54.47. 204,482 shares of the company’s stock traded hands. PAREXEL International has a one year low of $37.53 and a one year high of $57.25. The stock has a 50-day moving average of $53.88 and a 200-day moving average of $51.6. The company has a market cap of $3.098 billion and a price-to-earnings ratio of 26.32.

PAREXEL International (NASDAQ:PRXL) last released its earnings data on Wednesday, August 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.03. The company had revenue of $510.60 million for the quarter, compared to the consensus estimate of $508.99 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that PAREXEL International will post $2.67 EPS for the current fiscal year.

PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.

Receive News & Ratings for PAREXEL International Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co and related companies with Analyst Ratings Network's FREE daily email newsletter.